Novel insights into autoimmune liver diseases provided by genome-wide association studies

Journal of Autoimmunity

Volumn 46, Issue , 2013, Pages 41-54

  Mells, George F ^a   Kaser, Arthur ^a   Karlsen, Tom H ^b,c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF BERGEN   (Norway)

Author keywords

Autoimmune hepatitis; Genome wide association studies; Primary biliary cirrhosis; Primary sclerosing cholangitis

Indexed keywords

CLEC16A PROTEIN; HLA ANTIGEN; IMMUNOSUPPRESSIVE AGENT; INTERFERON REGULATORY FACTOR 5; INTERLEUKIN 12P35; LTBR PROTEIN; PREBIOTIC AGENT; PROBIOTIC AGENT; PROTEIN; SCHIP1 PROTEIN; STAT1 PROTEIN; STAT4 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; TNPO3 PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; AUTOIMMUNE LIVER DISEASE; AUTOIMMUNE THYROIDITIS; COMORBIDITY; DISEASE ASSOCIATION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE ENVIRONMENT INTERACTION; HIGH THROUGHPUT SCREENING; HLA SYSTEM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; JAPANESE; NONHUMAN; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; REVIEW; RISK; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS;

AUTOIMMUNE HEPATITIS; GENOME-WIDE ASSOCIATION STUDIES; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS;

AUTOIMMUNE DISEASES; CHOLANGITIS, SCLEROSING; GENE-ENVIRONMENT INTERACTION; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HEPATITIS, AUTOIMMUNE; HLA ANTIGENS; HUMANS; LIVER CIRRHOSIS, BILIARY; MODELS, GENETIC;

EID: 84886253518     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2013.07.004     Document Type: Review

References (128)

1. Lata J. Diagnosis and treatment of autoimmune hepatitis. Digestive Diseases 2012, 30:212-215.
2. Kaplan M.M., Gershwin M.E. Primary biliary cirrhosis. The New England Journal of Medicine 2005, 353:1261-1273.
3. Maggs J.R., Chapman R.W. An update on primary sclerosing cholangitis. Current Opinion in Gastroenterology 2008, 24:377-383.
4. Hoeroldt B., McFarlane E., Dube A., Basumani P., Karajeh M., Campbell M.J., et al. Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center. Gastroenterology 2011, 140:1980-1989.
5. Kumagi T., Guindi M., Fischer S.E., Arenovich T., Abdalian R., Coltescu C., et al. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. The American Journal of Gastroenterology 2010, 105:2186-2194.
6. Barnabas A., Chapman R.W. Primary sclerosing cholangitis: is any treatment worthwhile?. Current Gastroenterology Reports 2012, 14:17-24.
7. Bogdanos D.P., Mieli-Vergani G., Vergani D. Autoantibodies and their antigens in autoimmune hepatitis. Seminars in Liver Disease 2009, 29:241-253.
8. Kita H., Matsumura S., He X.S., et al. Quantitative and functional analysis of PDC-E2-specific autoreactive cytotoxic T lymphocytes in primary biliary cirrhosis. The Journal of Clinical Investigation 2002, 109:1231-1240.
9. Bogdanos D.P., Invernizzi P., Mackay I.R., Vergani D. Autoimmune liver serology: current diagnostic and clinical challenges. World Journal of Gastroenterology 2008, 14:3374-3387.
10. Chapman R., Cullen S. Etiopathogenesis of primary sclerosing cholangitis. World Journal of Gastroenterology 2008, 14:3350-3359.
11. Schrumpf E., Fausa O., Forre O., Dobloug J.H., Ritland S., Thorsby E. HLA antigens and immunoregulatory T cells in ulcerative colitis associated with hepatobiliary disease. Scandinavian Journal of Gastroenterology 1982, 17:187-191.
12. Chapman R.W., Varghese Z., Gaul R., Patel G., Kokinon N., Sherlock S. Association of primary sclerosing cholangitis with HLA-B8. Gut 1983, 24:38-41.
13. Angulo P., Peter J.B., Gershwin M.E., DeSotel C.K., Shoenfeld Y., Ahmed A.E., et al. Serum autoantibodies in patients with primary sclerosing cholangitis. Journal of Hepatology 2000, 32:182-187.
14. Saarinen S., Olerup O., Broome U. Increased frequency of autoimmune diseases in patients with primary sclerosing cholangitis. The American Journal of Gastroenterology 2000, 95:3195-3199.
15. Bergquist A., Lindberg G., Saarinen S., Broome U. Increased prevalence of primary sclerosing cholangitis among first-degree relatives. Journal of Hepatology 2005, 42:252-256.
16. Broome U., Grunewald J., Scheynius A., Olerup O., Hultcrantz R. Preferential V beta3 usage by hepatic T lymphocytes in patients with primary sclerosing cholangitis. Journal of Hepatology 1997, 26:527-534.
17. Teufel A., Weinmann A., Kahaly G.J., Centner C., Piendl A., Wörns M., et al. Concurrent autoimmune diseases in patients with autoimmune hepatitis. Journal of Clinical Gastroenterology 2010, 44:208-213.
18. Loftus E.V., Harewood G.C., Loftus C.G., Tremaine W.J., Harmsen W.S., Zinsmeister A.R., et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005, 54:91-96.
19. Lamberts L.E., Janse M., Haagsma E.B., van den Berg A.P., Weersma R.K. Immune-mediated diseases in primary sclerosing cholangitis. Digestive and Liver Disease 2011, 43:802-806.
20. Gershwin M.E., Selmi C., Worman H.J., Watnik M., Utts J., Lindor K.D., et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology 2005, 42:1194-1202.
21. Corpechot C., Chretien Y., Chazouilleres O., Poupon R. Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis. Journal of Hepatology 2010, 53:162-169.
22. Watt F.E., James O.F., Jones D.E. Patterns of autoimmunity in primary biliary cirrhosis patients and their families: a population-based cohort study. QJM: Monthly Journal of the Association of Physicians 2004, 97:397-406.
23. Feizi T., Naccarato R., Sherlock S., Doniach D. Mitochondrial and other tissue antibodies in relatives of patients with primary biliary cirrhosis. Clinical and Experimental Immunology 1972, 10:609-622.
24. Bergquist A., Montgomery S.M., Bahmanyar S., Olsson R., Danielsson A., Lindgren S., et al. Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitis. Clinical Gastroenterology and Hepatology 2008, 6:939-943.
25. Rust C., Beuers U. Overlap syndromes among autoimmune liver diseases. World Journal of Gastroenterology 2008, 14:3368-3373.
26. Czaja A.J. The variant forms of autoimmune hepatitis. Annals of Internal Medicine 1996, 125:588-598.
27. Kaya M., Angulo P., Lindor K.D. Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system. Journal of Hepatology 2000, 33:537-542.
28. van Buuren H.R., van Hoogstraten H.J.E., Terkivatan T., Schalm S.W., Vleggaar F.P. High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis. Journal of Hepatology 2000, 33:543-548.
29. Floreani A., Rizzotto E.R., Ferrara F., Carderi I., Caroli D., Blasone L., et al. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. The American Journal of Gastroenterology 2005, 100:1516-1522.
30. Chazouilleres O., Wendum D., Serfaty L., Montembault S., Rosmorduc O., Poupon R. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998, 28:296-301.
31. Poupon R., Chazouilleres O., Corpechot C., Chretien Y. Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis. Hepatology 2006, 44:85-90.
32. Abdo A.A., Bain V.G., Kichian K., Lee S.S. Evolution of autoimmune hepatitis to primary sclerosing cholangitis: a sequential syndrome. Hepatology 2002, 36:1393-1399.
33. Boonstra K., Beuers U., Ponsioen C.Y. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. Journal of Hepatology 2012, 56:1181-1188.
34. Jones D.E., Watt F.E., Metcalf J.V., Bassendine M.F., James O.F. Familial primary biliary cirrhosis reassessed: a geographically-based population study. Journal of Hepatology 1999, 30:402-407.
35. Yoshida O., Abe M., Furukawa S., Murata Y., Hamada M., Hiasa Y., et al. Afamilial case of autoimmune hepatitis. Internal Medicine 2009, 48:315-319.
36. Nozic D., Dimitrijevic J., Knezevic-Usaj S. Occurrence of autoimmune chronic hepatitis in siblings. Vojnosanitetski pregled 2005, 62:591-594.
37. Ohira H., Shinzawa J., Suzuki T., Tojo J., Sato H., Nishimaki T., et al. Two sister cases of autoimmune hepatitis. Fukushima Journal of Medical Science 1998, 44:113-120.
38. Jones D.E., Watt F.E., Grove J., Newton J.L., Daly A.K., Gregory W.L., et al. Tumour necrosis factor-alpha promoter polymorphisms in primary biliary cirrhosis. Journal of Hepatology 1999, 30:232-236.
39. Tanaka A., Quaranta S., Mattalia A., Coppel R., Rosina F., Manns M., et al. The tumor necrosis factor-alpha promoter correlates with progression of primary biliary cirrhosis. Journal of Hepatology 1999, 30:826-829.
40. Gordon M.A., Oppenheim E., Camp N.J., di Giovine F.S., Duff G.W., Gleeson D. Primary biliary cirrhosis shows association with genetic polymorphism of tumour necrosis factor alpha promoter region. Journal of Hepatology 1999, 31:242-247.
41. Fan L.Y., Zhu Y., Zhong R.Q., Tu X.Q., Pfeiffer T., Feltens R., et al. Genetic association between interleukins gene polymorphisms with primary biliary cirrhosis in Chinese population. Zhongguo Yi Xue Ke Xue Yuan Xue Bao Acta Academiae Medicinae Sinicae 2004, 26:505-509.
42. Donaldson P.T. TNF gene polymorphisms in primary biliary cirrhosis: a critical appraisal. Journal of Hepatology 1999, 31:366-368.
43. Hirschfield G.M., Liu X., Xu C., Lu Y., Xie G., Lu Y., et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. The New England Journal of Medicine 2009, 360:2544-2555.
44. Liu X., Invernizzi P., Lu Y., Kosoy R., Lu Y., Bianchi I., et al. Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nature Genetics 2010, 42:658-660.
45. Mells G.F., Floyd J.A., Morley K.I., Cordell H.J., Franklin C.S., Shin S.Y., et al. Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis. Nature Genetics 2011, 43:329-332.
46. Nakamura M., Nishida N., Kawashima M., Aiba Y., Tanaka A., Yasunami M., et al. Genome-wide association study identifies TNFSF15 and POU2AF1 as susceptibility loci for primary biliary cirrhosis in the Japanese population. American Journal of Human Genetics 2012, 91:721-728.
47. Juran B.D., Hirschfield G.M., Invernizzi P., Atkinson E.J., Li Y., Xie G., et al. Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. Human Molecular Genetics 2012, 21:5209-5221.
48. Liu J.Z., Almarri M.A., Gaffney D.J., Mells G.F., Jostins L., Cordell H.J., et al. Dense fine-mapping study identifies new susceptibility loci for primary biliary cirrhosis. Nature Genetics 2012, 44:1137-1141.
49. Hirschfield G.M., Liu X., Han Y., Gorlov I.P., Lu Y., Xu C., et al. Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis. Nature Genetics 2010, 42:655-657.
50. Karlsen T.H., Franke A., Melum E., Kaser A., Hov J.R., Balschun T., et al. Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology 2010, 138:1102-1111.
51. Melum E., Franke A., Schramm C., Weismüller T.J., Gotthardt D.N., Offner F.A., et al. Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nature Genetics 2011, 43:17-19.
52. Janse M., Lamberts L.E., Franke L., Raychaudhuri S., Ellinghaus E., Boberg K.M., et al. Three ulcerative colitis susceptibility loci are associated with primary sclerosing cholangitis and indicate a role for IL2, REL, and CARD9. Hepatology 2011, 53:1977-1985.
53. Folseraas T., Melum E., Rausch P., Juran B.D., Ellinghaus E., Shiryaev A., et al. Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci. Journal of Hepatology 2012, 57:366-375.
54. Srivastava B., Mells G.F., Cordell H.J., Muriithi A., Brown M., Ellinghaus E., et al. Fine mapping and replication of genetic risk loci in primary sclerosing cholangitis. Scandinavian Journal of Gastroenterology 2012, 47:820-826.
55. Ellinghaus D., Folseraas T., Holm K., Ellinghaus E., Melum E., Balschun T., et al. Genome-wide association analysis in sclerosing cholangitis and ulcerative colitis identifies risk loci at GPR35 and TCF4. Hepatology 2013, (in press). 10.1002/hep.25977.
56. Liu J.Z., Folseraas T., Ellinghaus E., Ellinghaus E., Rushbrook S.M., Doncheva N.T., et al. Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nature Genetics 2013, 45:670-675.
57. Kelley J., Trowsdale J. Features of MHC and NK gene clusters. Transplant Immunology 2005, 14:129-134.
58. Traherne J.A. Human MHC architecture and evolution: implications for disease association studies. International Journal of Immunogenetics 2008, 35:179-192.
59. Donaldson P.T., Farrant J.M., Wilkinson M.L., Hayllar K., Portmann B.C., Williams R. Dual association of HLA DR2 and DR3 with primary sclerosing cholangitis. Hepatology 1991, 13:129-133.
60. Spurkland A., Saarinen S., Boberg K.M., Mitchell S., Broome U., Caballeria L., et al. HLA class II haplotypes in primary sclerosing cholangitis patients from five European populations. Tissue Antigens 1999, 53:459-469.
61. Donaldson P.T., Norris S. Evaluation of the role of MHC class II alleles, haplotypes and selected amino acid sequences in primary sclerosing cholangitis. Autoimmunity 2002, 35:555-564.
62. McElroy J.P., Cree B.A., Caillier S.J., Gregersen P.K., Herbert J., Khan O.A., et al. Refining the association of MHC with multiple sclerosis in African Americans. Human Molecular Genetics 2010, 19:3080-3088.
63. Donaldson P.T. Genetics of liver disease: immunogenetics and disease pathogenesis. Gut 2004, 53:599-608.
64. Folseraas T., Melum E., Franke A., Karlsen T.H. Genetics in primary sclerosing cholangitis. Best Practice & Research Clinical Gastroenterology 2011, 25:713-726.
65. Dilthey A.T., Moutsianas L., Leslie S., McVean G. HLA IMP-an integrated framework for imputing classical HLA alleles from SNP genotypes. Bioinformatics 2011, 27:968-972.
66. Invernizzi P., Ransom M., Raychaudhuri S., Kosoy R., Lleo A., Shigeta R., et al. Classical HLA-DRB1 and DPB1 alleles account for HLA associations with primary biliary cirrhosis. Genes and Immunity 2012, 13:461-468.
67. Strettell M.D., Donaldson P.T., Thomson L.J., Santrach P.J., Moore S.B., Czaja A.J., et al. Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. Gastroenterology 1997, 112:2028-2035.
68. Yoshizawa K., Ota M., Katsuyama Y., Ichijo T., Matsumoto A., Tanaka E., et al. Genetic analysis of the HLA region of Japanese patients with type 1 autoimmune hepatitis. Journal of Hepatology 2005, 42:578-584.
69. Bittencourt P.L., Goldberg A.C., Cançado E.L., Porta G., Carrilho F.J., Farias A.Q., et al. Genetic heterogeneity in susceptibility to autoimmune hepatitis types 1 and 2. The American Journal of Gastroenterology 1999, 94:1906-1913.
70. Goldberg A.C., Bittencourt P.L., Mougin B., Cançado E.L., Porta G., Carrilho F., et al. Analysis of HLA haplotypes in autoimmune hepatitis type 1: identifying the major susceptibility locus. Human Immunology 2001, 62:165-169.
71. Czaja A.J., Kruger M., Santrach P.J., Moore S.B., Manns M.P. Genetic distinctions between types 1 and 2 autoimmune hepatitis. The American Journal of Gastroenterology 1997, 92:2197-2200.
72. Jurado A., Cardaba B., Jara P., Cuadrado P., Hierro L., de Andrés B., et al. Autoimmune hepatitis type 2 and hepatitis C virus infection: study of HLA antigens. Journal of Hepatology 1997, 26:983-991.
73. Cotsapas C., Voight B.F., Rossin E., Lage K., Neale B.M., Wallace C., et al. Pervasive sharing of genetic effects in autoimmune disease. PLoS Genetics 2011, 7:e1002254.
74. Hartley S.W., Monti S., Liu C.T., Steinberg M.H., Sebastiani P. Bayesian methods for multivariate modeling of pleiotropic SNP associations and genetic risk prediction. Frontiers in Genetics 2012, 3:176.
75. Jostins L., Ripke S., Weersma R.K., Duerr R.H., McGovern D.P., Hui K.Y., et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012, 491:119-124.
76. Hueber W., Patel D.D., Dryja T., Wright A.M., Koroleva I., Bruin G., et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Science Translational Medicine 2010, 2:52ra72.
77. Leonardi C., Matheson R., Zachariae C., Cameron G., Li L., Edson-Heredia E., et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. The New England Journal of Medicine 2012, 366:1190-1199.
78. Hueber W., Sands B.E., Lewitzky S., Vandemeulebroecke M., Reinisch W., Higgins P.D., et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012, 61:1693-1700.
79. Makamura M. Analysis of disease-pathway by identifying susceptibility genes to primary biliary cirrhosis. Nihon Rinsho Men'eki Gakkai kaishi 2012, 35:503-510.
80. Franke A., McGovern D.P., Barrett J.C., Wang K., Radford-Smith G.L., Ahmad T., et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nature Genetics 2010, 42:1118-1125.
81. Anderson C.A., Boucher G., Lees C.W., Franke A., D'Amato M., Taylor K.D., et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nature Genetics 2011, 43:246-252.
82. Bradfield J.P., Qu H.Q., Wang K., Zhang H., Sleiman P.M., Kim C.E., et al. Agenome-wide meta-analysis of six type 1 diabetes cohorts identifies multiple associated loci. PLoS Genetics 2011, 7:e1002293.
83. Marian A.J. Elements of 'missing heritability'. Current Opinion in Cardiology 2012, 27:197-201.
84. Trynka G., Hunt K.A., Bockett N.A., Romanos J., Mistry V., Szperl A., et al. Dense genotyping identifies and localizes multiple common and rare variant association signals in celiac disease. Nature Genetics 2011, 43:1193-1201.
85. Pritchard J.K., Cox N.J. The allelic architecture of human disease genes: common disease-common variant...or not?. Human Molecular Genetics 2002, 11:2417-2423.
86. Lundin K.E., Scott H., Fausa O., Thorsby E., Sollid L.M. Tcells from the small intestinal mucosa of a DR4, DQ7/DR4, DQ8 celiac disease patient preferentially recognize gliadin when presented by DQ8. Human Immunology 1994, 41:285-291.
87. Hugot J.P., Chamaillard M., Zouali H., Lesage S., Cézard J.P., Belaiche J., et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001, 411:599-603.
88. Hindorff L.A., Sethupathy P., Junkins H.A., Ramos E.M., Mehta J.P., Collins F.S., et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:9362-9367.
89. McGovern D.P., Jones M.R., Taylor K.D., Marciante K., Yan X., Dubinsky M., et al. Fucosyltransferase 2 (FUT2) non-secretor status is associated with Crohn's disease. Human Molecular Genetics 2010, 19:3468-3476.
90. Rausch P., Rehman A., Kunzel S., Häsler R., Ott S.J., Schreiber S., et al. Colonic mucosa-associated microbiota is influenced by an interaction of Crohn disease and FUT2 (Secretor) genotype. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:19030-19035.
91. Wacklin P., Makivuokko H., Alakulppi N., Nikkilä J., Tenkanen H., Räbinä J., et al. Secretor genotype (FUT2 gene) is strongly associated with the composition of Bifidobacteria in the human intestine. PLoS One 2011, 6:e20113.
92. Spor A., Koren O., Ley R. Unravelling the effects of the environment and host genotype on the gut microbiome. Nature Reviews in Microbiology 2011, 9:279-290.
93. Devkota S., Wang Y., Musch M.W., Leone V., Fehlner-Peach H., Nadimpalli A., et al. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10-/- mice. Nature 2012, 487:104-108.
94. Rowan F.E., Docherty N.G., Coffey J.C., O'Connell P.R. Sulphate-reducing bacteria and hydrogen sulphide in the aetiology of ulcerative colitis. British Journal of Surgery 2009, 96:151-158.
95. Cabre E., Domenech E. Impact of environmental and dietary factors on the course of inflammatory bowel disease. World Journal of Gastroenterology 2012, 18:3814-3822.
96. Franke A., Balschun T., Karlsen T.H., Sventoraityte J., Nikolaus S., Mayr G., et al. Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nature Genetics 2008, 40:1319-1323.
97. Daly A.K., Donaldson P.T., Bhatnagar P., Shen Y., Pe'er I., Floratos A., et al. HLA-B 5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nature Genetics 2009, 41:816-819.
98. Thomas D.L., Thio C.L., Martin M.P., Qi Y., Ge D., O'Huigin C., et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009, 461:798-801.
99. Fellay J., Thompson A.J., Ge D., Simon J.S., Shianna K.V., Urban T.J., et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 2010, 464:405-408.
100. Cani P.D., Delzenne N.M. The gut microbiome as therapeutic target. Pharmacology & Therapeutics 2011, 130:202-212.
101. Mells G., Hirschfield G.M. Genetics of primary biliary cirrhosis 2013, ELS: Wiley Online Library.
102. Schotte R., Rissoan M.C., Bendriss-Vermare N., Bridon J.M., Duhen T., Weijer K., et al. The transcription factor Spi-B is expressed in plasmacytoid DC precursors and inhibits T-, B-, and NK-cell development. Blood 2003, 101:1015-1023.
103. Becker A.M., Michael D.G., Satpathy A.T., Sciammas R., Singh H., Bhattacharya D. IRF-8 extinguishes neutrophil production and promotes dendritic cell lineage commitment in both myeloid and lymphoid mouse progenitors. Blood 2012, 119:2003-2012.
104. Tailor P., Tamura T., Ozato K. IRF family proteins and type I interferon induction in dendritic cells. Cell Research 2006, 16:134-140.
105. Honda K., Taniguchi T. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nature Reviews in Immunology 2006, 6:644-658.
106. Kaisho T., Tanaka T. Turning NF-kappaB and IRFs on and off in DC. Trends in Immunology 2008, 29:329-336.
107. Arthur J.S. MSK activation and physiological roles. Frontiers in Bioscience: A Journal and Virtual Library 2008, 13:5866-5879.
108. Cabal-Hierro L., Lazo P.S. Signal transduction by tumor necrosis factor receptors. Cellular Signalling 2012, 24:1297-1305.
109. Krausgruber T., Blazek K., Smallie T., Alzabin S., Lockstone H., Sahgal N., et al. IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nature Immunology 2011, 12:231-238.
110. Jin B., Sun T., Yu X.H., Yang Y.X., Yeo A.E. The effects of TLR activation on T-cell development and differentiation. Clinical & Developmental Immunology 2012, 2012:836485.
111. Watford W.T., Hissong B.D., Bream J.H., Kanno Y., Muul L., O'Shea J.J. Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. Immunological Reviews 2004, 202:139-156.
112. Tamiya T., Kashiwagi I., Takahashi R., Yasukawa H., Yoshimura A. Suppressors of cytokine signaling (SOCS) proteins and JAK/STAT pathways: regulation of T-cell inflammation by SOCS1 and SOCS3. Arteriosclerosis Thrombosis and Vascular Biology 2011, 31:980-985.
113. DeKoter R.P., Geadah M., Khoosal S., Xu L.S., Thillainadesan G., Torchia J., et al. Regulation of follicular B cell differentiation by the related E26 transformation-specific transcription factors PU.1, Spi-B, and Spi-C. Journal of Immunology 2010, 185:7374-7384.
114. Shin D.M., Lee C.H., Morse H.C. IRF8 governs expression of genes involved in innate and adaptive immunity in human and mouse germinal center B cells. PloS One 2011, 6:e27384.
115. Takenaka K., Fukami K., Otsuki M., Nakamura Y., Kataoka Y., Wada M., et al. Role of phospholipase C-L2, a novel phospholipase C-like protein that lacks lipase activity, in B-cell receptor signaling. Molecular and Cellular Biology 2003, 23:7329-7338.
116. Ma S., Pathak S., Mandal M., Trinh L., Clark M.R., Lu R. Ikaros and Aiolos inhibit pre-B-cell proliferation by directly suppressing c-Myc expression. Molecular and Cellular Biology 2010, 30:4149-4158.
117. Ma C.S., Deenick E.K., Batten M., Tangye S.G. The origins, function, and regulation of T follicular helper cells. The Journal of Experimental Medicine 2012, 209:1241-1253.
118. Bouillet P., Metcalf D., Huang D.C., Tarlinton D.M., Kay T.W., Köntgen F., et al. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 1999, 286:1735-1738.
119. Hildeman D.A., Zhu Y., Mitchell T.C., Bouillet P., Strasser A., Kappler J., et al. Activated T cell death invivo mediated by proapoptotic bcl-2 family member bim. Immunity 2002, 16:759-767.
120. Smeets R.L., Fleuren W.W., He X., Vink P.M., Wijnands F., Gorecka M., et al. Molecular pathway profiling of T lymphocyte signal transduction pathways; Th1 and Th2 genomic fingerprints are defined by TCR and CD28-mediated signaling. BMC Immunology 2012, 13:12.
121. Fallarini S., Magliulo L., Paoletti T., de Lalla C., Lombardi G. Expression of functional GPR35 in human iNKT cells. Biochemical and Biophysical Research Communications 2010, 398:420-425.
122. Hauser F., Deyle C., Berard D., Hauser F., Deyle C., Berard D., et al. Macrophage-stimulating protein polymorphism rs3197999 is associated with a gain of function: implications for inflammatory bowel disease. Genes and Immunity 2012, 13:321-327.
123. Dendrou C.A., Plagnol V., Fung E., Yang J.H., Downes K., Cooper J.D., et al. Cell-specific protein phenotypes for the autoimmune locus IL2RA using agenotype-selectable human bioresource. Nature Genetics 2009, 41:1011-1015.
124. Kasler H.G., Young B.D., Mottet D., Lim H.W., Collins A.M., Olson E.N., et al. Histone deacetylase 7 regulates cell survival and TCR signaling in CD4/CD8 double-positive thymocytes. Journal of Immunology 2011, 186:4782-4793.
125. Dequiedt F., Kasler H., Fischle W., Kiermer V., Weinstein M., Herndier B.G., et al. HDAC7, a thymus-specific class II histone deacetylase, regulates Nur77 transcription and TCR-mediated apoptosis. Immunity 2003, 18:687-698.
126. Dequiedt F., Van Lint J., Lecomte E., Van Duppen V., Seufferlein T., Vandenheede J.R., et al. Phosphorylation of histone deacetylase 7 by protein kinase D mediates T cell receptor-induced Nur77 expression and apoptosis. The Journal of Experimental Medicine 2005, 201:793-804.
127. Kamran N., Takai Y., Miyoshi J., Biswas S.K., Wong J.S., Gasser S. Toll-Like receptorligands induce expression of the Costimulatory molecule CD155 on antigen-presenting cells. PloS One 2013, 8:e54406.
128. Lozano E., Dominguez-Villar M., Kuchroo V., Hafler D.A. The TIGIT/CD226 axis regulates human T cell function. Journal of Immunology 2012, 188:3869-3875.